Cargando…
2276 Development of the expanded access oversight committee at Michigan Medicine
OBJECTIVES/SPECIFIC AIMS: Expanded Access is an avenue for patients with no available treatment options to access investigational drugs and devices for clinical therapy. This process requires physicians treating these patients to submit requests to the FDA and the local IRB, processes which are typi...
Autores principales: | Weatherwax, Kevin, Hutchinson, Ray, Mashour, George, Gravelin, Misty |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798686/ http://dx.doi.org/10.1017/cts.2018.281 |
Ejemplares similares
-
2489 Perceptions of “translation” and the application of research across disciplines at the University of Michigan
por: Gravelin, Misty, et al.
Publicado: (2018) -
400 Exploring the Diversity of Expanded Access Patients at Michigan Medicine
por: Gravelin, Misty, et al.
Publicado: (2023) -
Right now, in the right way: U. S. Food and Drug Administration’s expanded access program and patient rights
por: Holbein, M. E. Blair, et al.
Publicado: (2018) -
3371 The Devil is in the Details: Unbalanced Gains in Healthcare Access and Affordability in the Health Insurance Exchanges
por: Kim, Uriel, et al.
Publicado: (2019) -
2097 Johns Hopkins School of Medicine ClinicalTrials.gov Program challenges and successes
por: Keyes, Anthony, et al.
Publicado: (2018)